Search

Background and Aim: Cancer is a health problem that ranks second among the causes of death in the world and has a high mortality and morbidity rate. The most preferred systemic treatment method in cancer is chemotherapy. Chemotherapy has many side effects, depending on the treatment regimen used. Fatigue is one of the most common symptoms that cause many cognitive and physiological conditions in cancer patients. Therefore, aim of this study is to examine how fatigue affects anxiety, depression, and sleep quality of patients undergoing chemotherapy. Method: The data of this descriptive-cross-sectional study were obtained from 72 cancer patients over the age of 18 who agreed to participate in the study in a research hospital in Izmir between May 2020 and October 2020. 'Patient Information Form', 'Hospital Anxiety and Depression Scale (HADS), 'FACIT Fatigue Scale', and 'Pittsburgh Sleep Quality Index (PSQI)' were used to collect data. Results: As a result of the analysis, a statistically significant and positive correlation was found with a correlation coefficient of 0.468 for PSQI and FACIT and Depression subscale. A statistically significant, positive and moderate correlation was found with a correlation coefficient of 0.342 calculated between PSQI and Depression subscale. A statistically significant difference was found with a correlation coefficient of 0.616 calculated between the FACIT scale and the HADS. In the scales applied to the patients, it was determined that there were statistically significant differences only between the chemotherapy type, disease stage, and age from the descriptive characteristics of the patients. Conclusion and Recommendations: A high level of fatigue affects adversely patients' anxiety, depression and sleep quality. Planning interventions to control the factors that cause fatigue in patients undergoing chemotherapy will prevent them from experiencing other negative symptoms. [ABSTRACT FROM AUTHOR]

Purpose: This study aims to determine the financial toxicity (FT) level in cancer patients, identify the risk factors associated with this level, and reveal the effect of this level on patient outcomes (health-related quality of life (HRQoL) and treatment non-adherence). Methods: The data of 316 cancer patients, who were receiving inpatient treatment in an oncology hospital affiliated to a public university in Ankara, Turkey, were ≥ 18 years old, and were receiving chemotherapy for at least 3 months, were evaluated. The data were collected through a face-to-face interview. FT was measured with the COmprehensive Score for financial Toxicity (COST) Measure (v2), HRQoL was measured with the Functional Assessment of Cancer Therapy-General (FACT-G) Scale (v4), and treatment adherence was measured using a questionnaire created by conducting a literature review. Results: Patients were found to experience FT above the moderate level (mean ± SD, 21.85 ± 12.02; median value, 24.0). Younger age, being married, low education level, low monthly household income, and receiving social/economic support for treatment were revealed to be the determinants of high FT. Moreover, as the FT score decreased (as the FT level felt increased), the HRQoL was observed to decrease, and treatment non-adherence increased. Conclusion: The results indicate that FT problem is also valid for cancer patients in Turkey despite the system of general health insurance. The FT was found to result from socio-economic characteristics rather than the disease and treatment-related characteristics. The significant associations revealed between FT and patient outcomes emphasize the importance of reducing the FT in cancer patients. [ABSTRACT FROM AUTHOR]